Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma.

We describe a case of nivolumab immune-mediated neurotoxicity in a 42-year-old Hispanic man with relapsed Hodgkin lymphoma who presented with unilateral facial droop, dysarthria, and dysphagia 1 week after receiving nivolumab. His symptoms rapidly improved with steroids, intravenous immunoglobulin, and infliximab. PMID: 32063772 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/32063772?dopt=Abstract

Source: Baylor University Medical Center Proceedings - December 31, 2019 Category: Universities & Medical Training Authors: Lopez J, Yarlagadda N, Gheith Z, Mohan M, Sasapu A Tags: Proc (Bayl Univ Med Cent) Source Type: research